Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 4/20 | 0.60 |
| ▸ | GRB2 | P62993 | 13/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MLNR | O43193 | 1/20 | 0.45 |
| ▸ | CD2 | P06729 | 1/20 | 0.44 |
| ▸ | CD58 | P19256 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866020 | 1.00 | OXTR (0.60) | OXTRGRB2HDAC3HDAC1HDAC2 | |
| SCHEMBL27055536 | 0.88 | OXTR (0.49) | OXTRHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL27055602 | 0.84 | OXTR (0.47) | OXTRHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL29465932 | 0.81 | HDAC3 (0.57) | OXTRGRB2HDAC3HDAC1HDAC2 | |
| SCHEMBL29465925 | 0.81 | HDAC3 (0.57) | OXTRGRB2HDAC3HDAC1HDAC2 | |
| Bacillomycin D(C15) SCHEMBL29777429 | 0.81 | PLG (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| Bacillomycin D(C15) SCHEMBL27055650 | 0.81 | PLG (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL22725808 | 0.81 | KRAS (0.49) | OXTRGRB2HDAC3HDAC1HDAC2 | |
| SCHEMBL29465933 | 0.80 | HDAC3 (0.57) | OXTRGRB2HDAC3HDAC1HDAC2 | |
| SCHEMBL30928172 | 0.80 | PLG (0.49) | OXTRGRB2HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | claimed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | claimed |
| US-20230136991-A1 | ITURIN FAMILY LIPOPEPTIDES IN PEST CONTROL | INSTITUTE OF BIOLOGY, HEBEI ACADEMY OF SCIENCES (CN) | 2023-05-04 | — | — | US | claimed |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-20250270567-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025084927-A1 | MYCOSUBTILIN IN BAKERY PRODUCTS | MAURI TECHNOLOGY B.V. (NL) | 2025-04-24 | — | — | WO | disclosed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| US-12123004-B2 | Generation of acyl amino acids | MODULAR GENETICS, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| US-12031167-B2 | Generation of acyl amino acids | MODULAR GENETICS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4317461-A1 | CYCLIC LIPOPEPTIDE-PRODUCING MICROBIAL STRAIN AND METHOD FOR PRODUCING CYCLIC LIPOPEPTIDE | Kaneka Corporation (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-108347940-B | Microbial pesticide compositions and preparation thereof | 科.汉森有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | MODULAR GENETICS, INC. | 2022-08-18 | — | — | US | disclosed |
| CN-111019866-B | Endophytic bacillus of Pu' er tea tree leaves and application thereof | 华南理工大学 | 2022-08-16 | — | — | CN | disclosed |
| EP-4017265-A1 | FORMULATIONS FOR PREVENTION OR REDUCTION OF C. DIFFICILE INFECTIONS | SporeGen Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022040271-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FUNGAL DISEASES IN PLANTS | BAYER CROPSCIENCE LP (US) | 2022-02-24 | — | — | WO | disclosed |
| CN-113115777-B | Application of iturin family lipopeptide in pest control | 河北省科学院生物研究所 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | OXTR 4885/4885GRB2 3743/4885HDAC3 397/4885 |
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | OXTR 4744/4885GRB2 3768/4885HDAC3 300/4885 |
| US-20220259626-A1 | GENERATION OF ACYL AMINO ACIDS | FADS1, FADS2, FAR1 | OXTR 692/4885GRB2 1070/4885HDAC3 3704/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | OXTR 4718/4885GRB2 2060/4885HDAC3 3184/4885 |
| US-12031167-B2 | Generation of acyl amino acids | FADS1, FADS2, FAR1 | OXTR 692/4885GRB2 1070/4885HDAC3 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.